Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

Antipsychotic drug could help reduce nausea and vomiting caused by chemotherapy

A drug that blocks neurotransmitters could reduce nausea and vomiting caused by chemotherapy, research co-authored by a Sanford Health physician and published in the New England Journal of Medicine finds. [More]
Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Five-year survival data published online today in Blood, the Journal of the American Society of Hematology, suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies. [More]
New method helps characterize immune cells in tumor tissues

New method helps characterize immune cells in tumor tissues

Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them. Predictive markers of disease course and response to immunotherapy are urgently needed. [More]
Cancer immunotherapy could treat HIV

Cancer immunotherapy could treat HIV

A type of immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS. [More]
Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the OHSU Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate cancer. [More]
New treatment approach may benefit relapsed post-transplant blood cancer patients

New treatment approach may benefit relapsed post-transplant blood cancer patients

For many patients with advanced blood cancers, a stem-cell transplant can drive the disease into remission. However, about one-third of these patients experience a relapse and face a very poor prognosis. [More]
The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute is pleased to announce that the National Institutes of Health has awarded a nearly $23 million Martin Delaney Collaboratories for HIV Cure Research grant to the BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, a consortium of top HIV researchers led by co-principal investigators Luis J. Montaner, D.V.M., D.Phil., director of the HIV-1 Immunopathogenesis Laboratory at The Wistar Institute Vaccine Center, and James L. Riley, Ph.D., research associate professor at the Perelman School of Medicine at the University of Pennsylvania. [More]
UCLA scientists identify mechanisms of tumor resistance to immunotherapy in advanced melanoma

UCLA scientists identify mechanisms of tumor resistance to immunotherapy in advanced melanoma

UCLA researchers have for the first time identified mechanisms that determine how advanced melanoma can become resistant to immune checkpoint inhibitors, a discovery that could lead to the development of new and improved treatments for the deadliest type of skin cancer. [More]
Two new studies find potential genetic cause and new treatment method for autoimmune diseases

Two new studies find potential genetic cause and new treatment method for autoimmune diseases

The American Autoimmune Related Diseases Association, Inc. is spotlighting two new research studies originally reported in ScienceDaily. [More]
Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

Immunotherapy drug combination shows prominent therapeutic effect against advanced and metastatic cancers in mice

A drug combination designed to enhance the immune system's ability to zero in and attack cancer cells has shown a pronounced therapeutic effect against advanced and metastatic cancers in mice, according to a Mayo Clinic study, published in the July 12 edition of the online journal Oncotarget. [More]
Study shows how increase in BMI contributes to multiple myeloma growth and progression

Study shows how increase in BMI contributes to multiple myeloma growth and progression

In a new study published in Cancer Letters, American University researchers show how, as body mass index increases, so does the growth and spread of the blood cancer multiple myeloma, which accounts for about 10 percent of all blood cancers in patients. [More]
Immunotherapy cancer trials presented to key opinion leaders

Immunotherapy cancer trials presented to key opinion leaders

Immodulon recently met with some of the world’s most renowned oncologists to present their forthcoming trials for immunotherapy treatment, IMM-101. [More]
UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers develop new combination therapy to activate immune response against glioblastoma

UCLA researchers have developed a new breakthrough combination treatment that utilizes a vaccine to activate an immune response against advanced brain tumors. [More]
Inherited mutations in DNA repair genes may predispose to metastatic prostate cancer

Inherited mutations in DNA repair genes may predispose to metastatic prostate cancer

Inherited mutations in genes that function to repair DNA may contribute to metastatic prostate cancer more than previously recognized, according to a study out today in the New England Journal of Medicine. [More]
Added benefit of idelalisib drug not proven for patients with CLL

Added benefit of idelalisib drug not proven for patients with CLL

Already in 2014, the German Institute for Quality and Efficiency in Health Care examined in an early benefit assessment whether idelalisib offers advantages over the appropriate comparator therapy for patients with chronic lymphocytic leukaemia (CLL). [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
Immunotherapy in conjunction with drugs could be effective in treating pancreatic cancer

Immunotherapy in conjunction with drugs could be effective in treating pancreatic cancer

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies. [More]
Study could offer new ways to enhance cancer immunotherapy

Study could offer new ways to enhance cancer immunotherapy

When an immune T cell divides into two daughter cells, the activity of an enzyme called mTORC1, which controls protein production, splits unevenly between the progeny, producing two cells with different properties. [More]
Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data presented at the European Society for Medical Oncology's 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Scientists develop new vaccine to stimulate both innate and specific adaptive response

Scientists develop new vaccine to stimulate both innate and specific adaptive response

Though a variety of immunotherapy-based strategies are being used against cancer, they are often hindered by the inability of the immune response to enter the immunosuppressive tumor microenvironment and to effectively mount a response to cancer cells. [More]
Advertisement
Advertisement